

Senate Community Affairs Committee

ANSWERS TO ESTIMATES QUESTIONS ON NOTICE

HEALTH PORTFOLIO

Budget Estimates 2017 - 2018, 29 & 30 May 2017

Ref No: SQ17-000752

OUTCOME: 4 - Individual Health Benefits

Topic: Life Saving Drugs Program

Type of Question: Written Question on Notice

Senator: Watt, Murray

Question:

- a) It's been 3 years since the LSDP post-market review was first announced. What is the current status of the review, its findings and recommendations?
- b) What is the Department of Health's intention in publishing the report outlining the outcomes of the LSDP post-market review? When can stakeholders expect to see a copy of the outcomes recommended by the Independent Reference Group following the post-market review?
- c) In lieu of the outcomes or recommendations of the post-market review being made public, what does this mean for new medicines being listed on the LSDP?

Answer:

The release of the Life Saving Drugs Program (LSDP) review report, and the response to the report, are matters for government. While the outcomes of the review are under consideration, the LSDP is continuing to operate under existing guidelines, including for the assessment of new listing applications. The LSDP is continuing to provide life-saving medicines for patients who require them. This includes the listing of elosulfase alfa (Vimizim®) on the LSDP for the treatment of mucopolysaccharidosis Type IV A (MPS IV A), also known as Morquio A syndrome), from 1 August 2017.